Expands Haemonetics' Hospital portfolio with innovative fiber optic sensor technology for interventional cardiology

扩展Haemonetics的医院组合，采用创新的光纤传感器技术进行介入心脏病学

Significant commercial synergies with Haemonetics' existing Vascular Closure portfolio

与Haemonetics现有血管闭合组合的显着商业协同作用

Accelerates Haemonetics' transformational growth

加速血液学的转型增长

BOSTON, Oct. 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate..

波士顿，2023年10月10日/PRNewswire/-Haemonetics Corporation（NYSE:HAE），一家专注于提供创新医疗解决方案以推动更好的患者结果的全球医疗技术公司，以及OpSens，Inc。（TSX:OPS）（OTCQX:OPSSF），一家以医疗器械心脏病学为重点的公司，根据其专有的光学技术提供创新解决方案，今天宣布，他们已经达成了一项明确的协议，根据该协议，Haemonetics将在全部现金交易中以2.90加元的价格收购OpSens的所有已发行股份，按当前汇率计算，该股份价值约为2.53亿美元。。

OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. OpSens' core products include the SavvyWire®, the world's first and only sensor-guided 3-in-1 guidewire for TAVR procedures, that acts as pacing and pressure monitoring wire advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients, and the OptoWire®, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (FFR) and diastolic pressure ratio (dPR) to aid clinicians in the diagnosis and treatment of patients with coronary artery disease.

OpSens提供商业和临床验证的光学技术，主要用于介入心脏病学。OpSens的核心产品包括SavvyWire®，这是世界上第一个也是唯一一种用于TAVR手术的传感器引导的三合一导丝，可作为起搏和压力监测线，推进手术流程，缩短患者住院时间，以及OptoWire®，压力导丝旨在通过准确一致地测量分流量储备（FFR）和舒张压比（dPR）来帮助临床医生诊断和治疗冠状动脉疾病患者，从而改善临床结果。

OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications. .

OpSens还生产用于医疗设备和其他关键工业应用的一系列光纤传感器解决方案。 .

Stewart Strong, President, Global Hospital at Haemonetics, said, 'With the acquisition of OpSens, we expand our leadership in interventional cardiology and strengthen our foundation for additional growth and diversification. By leveraging OpSens' proprietary optical sensor technology, our global commercial infrastructure, and our relationships with the top US hospitals performing TAVR and PCI procedures, we have a powerful opportunity to improve standards of care for more physicians and patients worldwide.

Haemonetics全球医院总裁斯图尔特·斯特朗（Stewart Strong）表示，“随着OpSens的收购，我们扩大了介入心脏病学的领导地位，加强了我们进一步发展和多样化的基础。通过利用OpSens专有的光学传感器技术，我们的全球商业基础设施以及我们与执行TAVR和PCI程序的美国顶级医院的关系，我们有机会提高全球更多医生和患者的护理标准。

We are excited to welcome OpSens' talented team and look forward to advancing our shared commitment to maximizing patient benefits and value for our customers.'.

我们很高兴欢迎OpSens的才华横溢的团队，并期待推进我们为客户最大限度地提高患者利益和价值的共同承诺。

This transaction creates compelling financial and strategic benefits for Haemonetics:

这项交易为血液学带来了令人信服的财务和战略利益：

Expands Hospital business unit portfolio with innovative fiber optic sensor technology in the attractive interventional cardiology market. OpSens' portfolio utilized in TAVR and PCI procedures offers strong competitive advantages with a total addressable market of approximately $1 billion. OpSens technology is also being used across a range of medical and industrial applications, representing additional avenues for growth and diversification..

在有吸引力的介入心脏病学市场扩大医院业务部门与创新光纤传感器技术的组合。在TAVR和PCI程序中使用的OpSens组合提供了强大的竞争优势，总可寻址市场约为10亿美元。OpSens技术也被用于各种医疗和工业应用，代表了增长和多样化的其他途径。。

Leverages Haemonetics' commercial and geographic breadth to accelerate adoption. OpSens' product portfolio has already demonstrated commercial success and is well-positioned for long-term growth. Haemonetics' commercial success with its VASCADE® Vascular Closure portfolio, combined with extensive existing commercial and clinical infrastructure, will accelerate customer access to OpSens' products with the potential to make SavvyWire the leading guidewire for TAVR procedures in the U.S.

利用血液学的商业和地理广度来加速采用。OpSens的产品组合已经显示出商业成功，并且处于长期增长的良好位置。Haemonetics凭借其VASCADE®血管闭合产品组合取得的商业成功，结合广泛的现有商业和临床基础设施，将加速客户对OpSens产品的访问，并有可能使SAVVy成为美国TAVR程序的领先指导方针。

Additionally, Haemonetics' presence in high-growth international markets will enable further penetration of OpSens products in these regions..

此外，血液学在高增长国际市场的存在将使OpSens产品进一步渗透到这些地区。。

Augments long-term growth with additional product and market expansion opportunities. Haemonetics plans to build on the OpSens acquisition to further expand its Hospital business through internal and external R&D, clinical, and other business development efforts. Over the past several quarters, Haemonetics has made additional strategic investments, which would further complement OpSens' portfolio and strengthen Haemonetics' leadership in interventional cardiology, including in VivaSure Medical®, the company that developed PerQSeal®, an innovative percutaneous large-bore vessel closure technology..

通过额外的产品和市场扩张机会增加长期增长。Haemonetics计划以OpSens收购为基础，通过内部和外部研发，临床和其他业务开发工作进一步扩大医院业务。在过去的几个季度中，Haemonetics进行了额外的战略投资，这将进一步补充OpSens的产品组合，并加强Haemonetics在介入心脏病学领域的领导地位，其中包括开发PerQSeal®的公司in VivasureMedical®，这是一种创新的经皮大口径血管闭合技术。。

Delivers immediate and longer-term financial benefits. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter.

提供即时和长期的经济利益。预计该交易将立即增加血液学的收入增长。在GAAP的基础上，Haemonetics预计，由于交易和整合成本以及之后的吸积，这项交易将略微稀释2024财年每稀释份额的收益。

Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share..

Haemonetics预计这项交易将立即增加每稀释份额的调整收益。。

Transaction Details and Financing

交易细节和融资

The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature.

该交易将受到“商业公司法”（魁北克省）的安排的影响。收购的完成取决于OpSens股东的批准，收到法院和监管部门的批准，以及此类交易习惯的某些其他关闭条件。

The transaction is expected to close by the end of January 2024..

该交易预计将于2024年1月底结束。。

Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x.

Haemonetics计划通过现金和旋转信贷机构的组合为此次收购提供资金。收购后，根据公司现有信用协议中规定的条款，Haemonetics的净债务与EBITDA比率预计约为2.1倍。

Advisors

顾问

Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and DLA Piper as legal advisor. Piper Sandler LLC served as OpSens' financial advisor, while Norton Rose Fulbright served as its legal advisor.

Goldman-Sachs＆Co。LLC担任Haemonetics的财务顾问，DLA Piper担任法律顾问。Piper Sandler LLC担任OpSens的财务顾问，而Norton Rose Fulbright担任其法律顾问。

Supplemental Information

补充信息

Haemonetics posted supplemental slides with additional information about this transaction to Haemonetics' investor relations website. These slides can also be accessed by following this link: https://haemonetics.gcs-web.com/static-files/7e0041fd-89d4-4f20-bbd0-947c00118c05

Haemonetics向Haemonetics的投资者关系网站发布了有关此交易的补充幻灯片。这些幻灯片也可以通过以下链接访问：https://haemonetics.gcs-web.com/static-files/7e0041fd-89d4-4f20-bbd0-947c00118c05

About Haemonetics

关于血液学

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.

Haemonetics（纽约州：HAE）是一家全球医疗保健公司，致力于为客户提供一套创新的医疗产品和解决方案，帮助他们改善患者护理并降低医疗成本。我们的技术涉及重要的医疗市场：血液和血浆成分收集，手术室和医院输血服务。

To learn more about Haemonetics, visit www.haemonetics.com..

要了解有关Haemonetics的更多信息，请访问www.Haemonetics.com。。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'forecasts,' 'foresees,' 'potential' and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for the operation of Haemonetics, (ii) statements regarding the timing of completion of the acquisition and the consummation of the acquisition, (iii) the anticipated financing of the transaction and the Company's net debt to EBITDA ratio following completion of the acquisition, (iv) the anticipated benefits to Haemonetics arising from the completion of the acquisition, (v) the impact of the acquisition on Haemonetics' business strategy and future business and operational performance, and (vi) the assumptions underlying or relating to any such statement.

本新闻稿包含1933年“证券法”第27A条和1934年“证券交易法”第21E条含义内的前瞻性陈述。前瞻性陈述与历史或当前事实并不严格相关，可以通过使用诸如“可能”，“将会”，“应该”，“可以”，“将会”，“期望”，“计划，“预期”，“相信”，“估计”，“项目”，“预测”，“预测”，“预见”，“潜在”和其他具有类似含义的词语以及关于除其他外，（i）Haemonetics运营管理的计划和目标，（ii）关于收购完成时间和收购完成的陈述，（iii）交易的预期融资以及公司完成后的净债务与EBITDA比率，（iv）收购完成后对血液学的预期收益，（v）收购对血液学业务战略以及未来业务和运营绩效的影响，以及（vi）任何此类声明所依据或与之相关的假设。

Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences.

这种前瞻性陈述并不意味着预测或保证实际结果，表现，事件或情况，并且可能无法实现，因为它们是基于血液学当前的预测，计划，目标，信念，期望，估计和假设，并且受制于一些风险和不确定性以及其他影响。

Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties..

由于这些风险和不确定性，实际结果以及某些事件和情况的发生时间可能与前瞻性声明中描述的发生重大差异。。

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the failure to realize the anticipated benefits of the acquisition or the acquisition, its announcement or pendency having an unanticipated impact, Haemonetics' ability to predict accurately the demand for products and products under development by it or OpSens and to develop strategies to successfully address relevant markets, the impact of competitive products and pricing, technical innovations that could render products marketed or under development by Haemonetics or OpSens obsolete, risks related to the use and protection of intellectual property, the risk that the transaction may not be completed in a timely manner or at all (whether due to the failure of OpSens to obtain shareholder approval, the failure to obtain approval of the Québec Superior Court or otherwise), and the risk that using debt to finance, in part, the acquisition will increase Haemonetics' indebtedness.

可能影响或导致前瞻性陈述不准确或导致实际结果与预期或预期结果大不相同的因素可能包括但不限于未能实现收购或收购的预期收益，其公告或pendence有意想不到的影响，Haemonetics能够准确预测it或OpSens正在开发的产品和产品的需求，并制定成功应对相关市场的策略，竞争性产品和定价的影响，可以使Haemonetics或OpSens销售或开发产品的技术创新过时，与使用和保护知识产权有关的风险，交易可能无法及时或根本完成的风险（无论是由于OpSens未能获得股东批准，未能获得魁北克高等法院的批准）或其他），以及使用债务融资的风险，部分是收购将增加血液学的债务。

These and other factors are identified and described in more detail in Haemonetics' filings with the U.S. Securities and Exchange Commission ('SEC'). Haemonetics does not undertake to update these forward-looking statements..

这些因素和其他因素在Haemonetics与美国证券交易委员会（'SEC'）的文件中有更详细的描述和描述。Haemonetics不承诺更新这些前瞻性陈述。。

Non-GAAP Financial Measures

非GAAP财务措施

This press release contains financial measures that are considered 'non-GAAP' financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results.

本新闻稿包含根据适用的SEC规则和法规被视为“非GAAP”财务措施的财务措施。管理层使用非GAAP措施来监控业务的财务绩效，做出明智的业务决策，建立预算并预测未来结果。

Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the expected impact of the Company's acquisition of OpSens and provide a baseline for analyzing trends in the Company's underlying businesses.

管理绩效目标也基于某些非GAAP财务措施。这些非GAAP财务措施应被视为对公司根据美国GAAP编制的报告财务结果的补充，而不是替代。在此版本中，已提供补充的非GAAP措施，以帮助投资者评估公司收购OpSens的预期影响，并为分析公司基础业务的趋势提供基准。

We strongly encourage investors to review the Company's financial statements and publicly-filed reports in their entirety and not rely on any single financial measure..

我们强烈鼓励投资者全面审查公司的财务报表和公开提交的报告，而不依赖任何单一的财务措施。。

When used in this release, adjusted earnings per diluted share excludes restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation ('MDR') and In Vitro Diagnostic Regulation ('IVDR'), integration and transaction costs, certain tax settlements and unusual or infrequent and material litigation-related charges, and the tax impact of these items.

在本版本中使用时，每稀释份额调整后的收益不包括重组成本，重组相关成本，数字转换成本，收购无形资产的分摊，资产减值，加速器械折旧和相关成本，与遵守欧盟医疗器械有关的成本法规（'MDR'）和体外诊断法规（'IVDR'），整合和交易成本，某些税收解决方案以及与异常或罕见和物质诉讼相关的费用，以及这些项目的税收影响。

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies..

由于非GAAP财务措施不规范，因此可能无法将这些财务措施与其他公司使用的类似标题的措施进行比较。。

The Company does not attempt to provide reconciliations of forward-looking adjusted earnings per diluted share guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs and impairment charges, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts.

本公司并不试图将每稀释一股的前瞻性调整收益与可比较的GAAP指标进行核对，因为确认某些潜在费用或收益（如重组成本和减值费用）的综合影响和时间本质上是不确定的，难以预测，如果没有不合理的努力就无法实现。

In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company's financial performance..

此外，公司认为这种对帐意味着一定程度的精确性和确定性，可能会让投资者感到困惑。这些项目可能会对公司财务绩效的GAAP衡量标准产生重大影响。。

Additional Information Regarding the Transaction

有关交易的其他信息

In connection with the proposed transaction, OpSens will file with the Canadian Securities Administrators in each of the provinces of Canada (the 'CSA') and mail or otherwise make available to its shareholders a management information circular (the 'Proxy Circular') regarding the proposed transaction.

关于拟议交易，OpSens将向加拿大各省的加拿大证券管理员（“CSA”）提交文件，并向股东邮寄或以其他方式提供有关管理信息通知（“代理通知”）建议的交易。

BEFORE MAKING ANY VOTING DECISION, OPSENS' SHAREHOLDERS ARE URGED TO READ THE PROXY CIRCULAR IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED WITH THE CSA IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

在作出任何投票决定之前，敦促OPSENS的股东在代理循环可用时完整阅读代理循环，并向CSA提交与拟议交易有关或通过引用并入其中的任何其他文件，因为它们将包含有关拟议交易。

Investors and security holders may obtain a free copy of the Proxy Statement and other documents that OpSens files with the CSA (when available) from the CSA's website at www.sedarplus.ca and from OpSens' website at www.opsens.com..

投资者和担保人可以从CSA的网站www.sedarplus.ca和OpSens的网站www.OpSens.com上获得代理声明和其他文件的免费副本，这些文件与CSA一起提交（如果有的话）。。

Investor Contacts:

投资者联系方式：

Olga Guyette, Sr. Director-Investor Relations & Treasury

Olga Guyette，总经理投资者关系与财政部

David Trenk, Manager-Investor Relations

投资者关系经理David Trenk

(781) 356-9763

(781) 356-9763

(203) 733-4987

(203) 733-4987

[email protected]

[电子邮件保护]

[email protected]

[电子邮件保护]

Media Contact:

媒体联系：

Josh Gitelson, Director-Global Communications

全球通讯总监Josh Gitelson

(781) 356-9776

(781) 356-9776

[email protected]

[电子邮件保护]

SOURCE Haemonetics Corporation

来源Haemonetics公司